Newbury Pharmaceuticals expands the team with a Head of Business Development
Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Newbury Pharmaceuticals via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2022-08-02 14:30:00
Newbury Pharmaceuticals is pleased to announce the appointment of Mrs. Andrea Karnitschky as Senior Director and Head of Business Development. From August 1st 2022, Andrea Karnitschky’s responsibilities include the expansion of the pipeline and the development of strategic partnerships.
“We are very pleased to strengthen our team with Andrea who has an impressive track record in deal making. Andrea will be an important addition to Newbury, and I look forward to the collaboration to further grow our strong pipeline with new products and new exciting business opportunities”, says Lars Minor, CEO, Newbury Pharmaceuticals.
Prior to joining Newbury, Andrea Karnitschky held a position as Director & Head of In-licensing Europe at Dr. Reddy´s Laboratories SA following an appointment as Head of Sourcing at betapharm Arzneimittel GmbH. Andrea Karnitschky has a broad and deep network within the global pharmaceutical industry.
“I am excited to join Newbury – a young, dynamic, entrepreneurial company with high ambitions. It will be an interesting challenge to contribute to the growth of Newbury.” says Andrea Karnitschky.